Brooke Gile
Researcher in Simmaron Research's laboratory in Milwaukee who works on low-dose rapamycin as a possible treatment for ME/CFS and led the 2026 analysis of its effects on purine metabolism
Research and Development Lab, Simmaron Research, at the University of Wisconsin-Milwaukee (papers 2025–2026)
ME/CFS (myalgic encephalomyelitis/chronic fatigue syndrome) is a long-term illness with severe fatigue that gets worse after effort. Simmaron Research, a non-profit research group, has been testing whether low doses of rapamycin, a drug that blocks mTOR, can ease it. Brooke Gile was first author of the 2026 Atlas study from this programme (GIL2026). In patients who improved on rapamycin, blood levels of several purines, small molecules used to build DNA and carry energy, shifted in a pattern that fits lower activity of the enzyme IMP dehydrogenase in white blood cells. In lab experiments, the same purine changes harmed mitochondria and made microglia, the brain's immune cells, more inflammatory.
The study had no placebo group, so it cannot show that rapamycin caused the improvement in fatigue. The links to mitochondria and microglia come from lab tests and were not measured in the patients themselves.
Gile was also a co-author of the first paper from the same trial, published in 2025, which reported that 6 mg of rapamycin a week was tolerated without serious side effects and that most patients who stayed in the study reported less fatigue, with blood markers suggesting better autophagy, the cell's recycling system. PubMed lists Gile at the Simmaron Research and Development Lab at the University of Wisconsin-Milwaukee in that paper. No personal page was found, so training and job title are not shown.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2026 | H | Association of rapamycin treatment with the modulation of purine metabolism, reduced microglial inflammatory responses, improved mitochondrial energy metabolism, and alleviation of fatigue symptoms in ME/CFS subjects: pilot findings from phase-II observational study GIL2026 First author: linked rapamycin response in an uncontrolled ME/CFS pilot to shifts in blood purines and tested the purine effects on mitochondria and microglia in the lab. |
Co-authors in the Atlas 1
People with a profile here who share at least one study with Brooke Gile.
ShowHide
- Avik Roy Neuroscientist who studies brain inflammation in Parkinson's disease and now leads research on ME/CFS as Chief Scientific Officer of the nonprofit Simmaron Research
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.